Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6716-6733

[No Author Info available]

Author keywords

Chemotherapy; Eukaryotic translation initiation factor 5A2; Hepatocellular carcinoma; Matrix Metalloproteinase 2; Vasculature remodeling

Indexed keywords

COLLAGEN TYPE 4; EUKARYOTIC INITIATION FACTOR 5A2; FLUOROURACIL; GELATINASE A; INITIATION FACTOR 5A; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; INITIATION FACTOR; MMP2 PROTEIN, HUMAN; RNA BINDING PROTEIN; SMALL INTERFERING RNA;

ADULT; ARTICLE; ASSAY; BASEMENT MEMBRANE; BIOASSAY; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FLUORESCENCE ANALYSIS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; RISK ASSESSMENT; TISSUE OXYGENATION; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE; TUMOR HYPOXIA ASSAY; TUMOR PERFUSION ASSAY; TUMOR VASCULARIZATION; TUMOR VASCULATURE REMODELING; UPREGULATION; ANIMAL; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; DRUG SCREENING; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE INITIATION FACTORS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907084184     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2236     Document Type: Article

References (46)

1. El-Serag HB and Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C and Zeuzem S. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
3. Guan XY, Sham JS, Tang TC, Fang Y, Huo KK and Yang JM. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 2001; 61:3806-3809.
4. Wang FW, Guan XY and Xie D. Roles of Eukaryotic Initiation Factor 5A2 in Human Cancer. Int J Biol Sci 2013; 9:1013-1020.
5. Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, Xie D, Zhang Y, Hu L, Wu QL, Fang Y and Sham JS. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res 2004; 64:4197-4200.
6. Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, Lau SH, Li Y, Li Y and Guan XY. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 2010; 51:1255-1263.
7. Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, Guan XY and Xie D. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut 2012; 61:562-575.
8. Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, Dong S, Guan XY, Poon RT and Luk JM. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer 2010; 127:968-76.
9. Li Y, Fu L, Li JB, Qin Y, Zeng TT, Zhou J, Zeng ZL, Chen J, Cao TT, Ban X, Qian C, Cai Z and Xie D. Increased expression of EIF5A2, via hypoxia of gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology. 2014; [Epub ahead of print].
10. Yang ZF and Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken) 2008; 291:721-734.
11. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3:422-433.
12. Kuhn K, Wiedemann H, Timpl R, Risteli J, Dieringer H, Voss T and Glanville RW. Macromolecular structure of basement membrane collagens. FEBS Lett 1981; 125:123-128.
13. Timpl R, Wiedemann H, van Delden V, Furthmayr H and Kuhn K. A network model for the organization of type IV collagen molecules in basement membranes. Eur J Biochem 1981; 120:203-211.
14. Simon C, Goepfert H and Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998; 58:1135-1139.
15. Westermarck J and Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13:781-792.
16. Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C and and Kahari VM. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 2000; 113(Pt 2):227-235.
17. Zhu YH, Fu L, Chen L, Qin YR, Liu H, Xie F, Zeng T, Dong SS, Li J, Li Y, Dai Y, Xie D and Guan XY. Downregulation of the novel tumor suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Res 2013; 73:2298-2309.
18. Hong IK, Kim YM, Jeoung DI, Kim KC and Lee H. Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK, JNK and c-Jun pathways in human melanoma cells. Exp Mol Med 2005; 37:230-239.
19. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049.
20. Carmeliet P and Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
21. Khosravi S, Wong RP, Ardekani GS, Zhang G, Martinka M, Ong CJ and Li G. Role of EIF5A2, a downstream target of Akt, in promoting melanoma 2014; 110:399-408.
22. Kessenbrock K, Plaks V and Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67.
23. Zheng L, Li D, Xiang X, Tong L, Qi M, Pu J, Huang K and Tong Q. Methy jasmonate abolishes the migration, invasion and angiogenesis of gastric cancer cells through down-regulation of matrix metalloproteinase 14. BMC Cancer 2013; doi:10.101186/1471-2407-13-74.
24. Haas TL, Stitelman D, Davis SJ, Apte SS and Madri JA. Egr-1 mediates extracelluar matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 1999; 274:22679-85.
25. Ben-Yosef Y, Miller A, Shapiro S and Lahat N. Hypoxia of endothelial cells leads to MMP2-dependent survival and death. Am J Physiol Cell Physiol 2005; 289:C1321-31.
26. Shapiro S, Khodalev O, Bitterman H, Auslender R and Lahat N. Different activation forms of MMP-2 oppositely affect the fate of endothelial cells. Am J Physiol Cell Physiol. 2010; 298:C942-51.
27. Hubmacher D and Apte SS. The biology of the extracellular matrix: novel insights. Curr Opin Rheumatol 2013; 25:65-70.
28. Bergers G and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
29. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109:2784-2789.
30. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S and Aragones J. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136:839-851.
31. Leite de Oliveira R, Deschoemaeker S, Henze AT, Debackere K, Finisguerra V, Takeda Y, Roncal C, Dettori D, Tack E, Jonsson Y, Veschini L, Peeters A, Anisimov A and et al. Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 2012; 22:263-277.
32. Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY and and Zhuang SM. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011; 54:1729-1740.
33. Liu P, Du F, Chen W, Yao M, Lv K and Fu P. EIF5A2 is a novel chemoresistance gene in breast cancer. Breast Cancer 2014; [Epub ahead of print].
34. Wei JH, Cao JZ, Zhang D, Liao B, Zhong WM, Lu J, Zhao HW, Zhang JX, Tong ZT, Fan S, Liang CZ, Liao YB, Pang J and et al. EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo. Br J Cancer 2014; 110:1767-77.
35. Yang J, Yu H, Shen M, Wei W, Xia L and Zhao P. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activiation. Cancer Sci 2014; [Epub ahead of print].
36. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW and and Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25:2586-2593.
37. Sobin LH and Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80:1803-1804.
38. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y, Hu L and and Guan XY. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003; 107:896-902.
39. Jiang L, Lin C, Song L, Wu J, Chen B, Ying Z, Fang L, Yan X, He M, Li J, Li M. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xeotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J Clin Invest 2012; 122:33-47.
40. Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ, Huang J and Guan XY. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut 2011; 60:534-543.
41. Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, Pelat M, Ghisdal P, Gregoire V, Dessy C, Balligand JL and Feron O. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res 2004; 95:154-161.
42. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL and and Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553-563.
43. Fukumura D and Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74:72-84.
44. Huang Y, Song N, Ding Y, Yuan S, Li X, Cai H, Shi H and Luo Y. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 2009; 69:7529-7537.
45. Camp RL, Dolled-Filhart M and Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10:7252-7259.
46. Raeside DE. Monte Carlo principles and applications. Phys Med Biol 1976; 21:181-197.